Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy

被引:7
|
作者
Graner, Sofie [1 ,2 ]
Mc Taggart, Julia [3 ]
Nordstrom, Fanny [3 ]
Melander, Emma [3 ]
Widenberg, Johan [4 ]
Kallner, Helena Kopp [3 ,4 ,5 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp, Dept Med, Ctr Pharmacoepidemiol, Stockholm, Sweden
[2] Danderyd Hosp, Matern BB Stockholm, Stockholm, Sweden
[3] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden
[4] Danderyd Hosp, Dept Obstet & Gynecol, Stockholm, Sweden
[5] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden
关键词
Ectopic pregnancy; intrauterine contraception; levonorgestrel containing intrauterine system; levonorgestrel containing intrauterine system 13; 5; mg; levonorgestrel containing intrauterine system 52 mg; Pearl index; LNG-IUS; 8; PHASE-III; SINGLE-ARM; MULTICENTER; PROGESTASERT; SAFETY;
D O I
10.1111/aogs.13564
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction The objective was to investigate the Pearl index for ectopic pregnancy in women using the levonorgestrel intrauterine system (LNG-IUS) at the time of conception. Material and methods This was a substudy of a hospital-based historical cohort including women with an ectopic pregnancy diagnosed in 4 referral hospitals in Stockholm, Sweden between December 2013 and April 2017. Study participants and type of contraception at time of conception were identified through the electronic medical chart system. Cases were defined as women with LNG-IUS 13.5 or 52 mg in situ at the time of diagnosis of ectopic pregnancy who had their LNG-IUS inserted 1 January 2014 or later. Outcome was defined as the incidence rate for ectopic pregnancy during use per 100 woman-years (Pearl index) with 95% confidence interval (95% CI). Results The study includes 35 cases with LNG-IUS 13.5 mg and 13 cases with LNG-IUS 52 mg, which occurred in 18 488 (13.5 mg) and 50 246 (52 mg) exposed woman-years. Pearl index for ectopic pregnancy was estimated at 0.19 (95% CI 0.15-0.28) for LNG-IUS 13.5 mg and to 0.006 (95% CI 0.00-0.01) for LNG-IUS 52 mg. The most cases for the LNG-IUS 13.5 mg (n = 26; 74%) occurred during the first year of use with a corresponding Pearl index at 0.23 (95% CI 0.14-0.35). Conclusions The absolute risk of ectopic pregnancy during the use of LNG-IUS remains low. Our method may underestimate as well as overestimate the Pearl index for ectopic pregnancy. The findings underline the importance of identifying risk factors for ectopic pregnancy at insertion, and to rule out ectopic pregnancy for all women presenting with abdominal discomfort during the use of LNG-IUS. Longer observation periods and prospective studies in a general population are a priority for further research.
引用
收藏
页码:937 / 943
页数:7
相关论文
共 50 条
  • [21] User satisfaction with an intrauterine system containing 52 mg levonorgestrel: a Portuguese study
    Nogueira-Silva, Cristina
    Rolhas, Ana
    Ramilo, Irina
    Plancha, Marta
    da Silva, Daniel Pereira
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2023, 28 (02): : 113 - 118
  • [22] Impact of training level on postplacental levonorgestrel 52 mg intrauterine device expulsion
    Cole, Madeline
    Thomas, Stephanie
    Mercer, Brian M.
    Arora, Kavita Shah
    CONTRACEPTION, 2019, 99 (02) : 94 - 97
  • [23] Heavy Menstrual Bleeding Treatment With a Levonorgestrel 52-mg Intrauterine Device
    Creinin, Mitchell D.
    Barnhart, Kurt T.
    Gawron, Lori M.
    Eisenberg, David
    Mabey, R. Garn
    Jensen, Jeffrey T.
    OBSTETRICS AND GYNECOLOGY, 2023, 141 (05): : 971 - 978
  • [24] Time to removal and predictors of removal of the levonorgestrel 52-mg intrauterine system
    Creinin, M. D.
    Harrington, A.
    Baradaran, S.
    Guo, L.
    Ye, J.
    Olariu, A. I.
    CONTRACEPTION, 2018, 98 (04) : 351 - 351
  • [25] LEVONORGESTREL 52 MG INTRAUTERINE DEVICE PLACEMENT WITHOUT SOUNDING: A FEASIBILITY STUDY
    Brown, J.
    Yazdani, S.
    Economou, N.
    Flynn, A.
    Rankin, H.
    Creinin, M. D.
    CONTRACEPTION, 2024, 139
  • [26] Extending use of 52-mg levonorgestrel intrauterine systems to 8 years: bridging phases of life
    Goldberg, Alisa B.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 227 (06) : 803 - 804
  • [27] Ovarian cysts: presence and persistence with use of a 13.5 mg levonorgestrel-releasing intrauterine system
    Nahum, Gerard G.
    Kaunitz, Andrew M.
    Rosen, Kimberly
    Schmelter, Thomas
    Lynen, Richard
    CONTRACEPTION, 2015, 91 (05) : 412 - 417
  • [28] Ectopic pregnancy with levonorgestrel releasing intrauterine system
    Ojutiku, D
    Cutner, A
    Rymer, J
    BRITISH JOURNAL OF FAMILY PLANNING, 1998, 24 (02): : 85 - 86
  • [29] Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg
    Teunissen, Anna M.
    Merry, Audrey H. H.
    Devies, Ingrid E. C.
    Roumen, Frans J. M. E.
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2019, 24 (06): : 449 - 456
  • [30] ECTOPIC PREGNANCY AND INTRAUTERINE CONTRACEPTIVE DEVICE
    PORGES, RF
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1974, 118 (08) : 1155 - 1155